Trivli Alexandra, Koliarakis Ioannis, Terzidou Chryssa, Goulielmos George N, Siganos Charalambos S, Spandidos Demetrios A, Dalianis Georgios, Detorakis Efstathios T
Department of Ophthalmology, Konstantopouleio-Patission General Hospital, 14233 Athens, Greece.
Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Exp Ther Med. 2019 Jan;17(1):563-574. doi: 10.3892/etm.2018.7011. Epub 2018 Nov 26.
Normal-tension glaucoma (NTG) is a multifactorial optic neuropathy which, similar to open-angle glaucomas, is characterized by progressive retinal ganglion cell death and glaucomatous visual field loss. The major distinction of NTG from open-angle glaucomas is that the intraocular pressure (IOP) does not exceed the normal range. Missing the major risk factor and target of therapy, the elevated IOP, NTG poses a clinical challenge. Several insightful reviews have been published on the pathophysiology of NTG describing the possible underlying mechanisms. The current literature available also suggests that a significant percentage of patients with NTG (as high as 21%) have a family history of glaucoma, indicating a genetic predisposition to the disease. These facts strengthen the indication that NTG remains an enigmatic process. The aim of this review was to summarize the vascular, mechanical and genetic components considered to be responsible for NTG development and to discuss the mechanisms through which they are involved in the pathogenesis of NTG.
正常眼压性青光眼(NTG)是一种多因素性视神经病变,与开角型青光眼相似,其特征为视网膜神经节细胞进行性死亡和青光眼性视野缺损。NTG与开角型青光眼的主要区别在于眼压(IOP)不超过正常范围。由于缺少主要危险因素和治疗靶点——升高的眼压,NTG带来了临床挑战。关于NTG的病理生理学已发表了几篇有见地的综述,描述了可能的潜在机制。现有文献还表明,相当比例的NTG患者(高达21%)有青光眼家族史,提示该病存在遗传易感性。这些事实进一步表明NTG仍是一个谜一样的过程。本综述的目的是总结被认为与NTG发生相关的血管、机械和遗传因素,并讨论它们参与NTG发病机制的途径。
Exp Ther Med. 2019-1
Indian J Ophthalmol. 2024-5-1
Nippon Ganka Gakkai Zasshi. 2015-3
Cesk Slov Oftalmol. 2019
Biomed Res Int. 2015
Curr Opin Ophthalmol. 2008-3
Indian J Ophthalmol. 2014-5
Eye Brain. 2023-4-6
Pharmaceuticals (Basel). 2023-8-17
Transl Vis Sci Technol. 2025-4-1
Naunyn Schmiedebergs Arch Pharmacol. 2025-4
Front Ophthalmol (Lausanne). 2024-1-17
Clin Ophthalmol. 2024-2-22
Indian J Ophthalmol. 2024-5-1
Invest Ophthalmol Vis Sci. 2017-5-1
Acta Ophthalmol. 2017-11
Asia Pac J Ophthalmol (Phila). 2016
Biomed Res Int. 2015